Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine (Butantan-DV) in Patients With Autoimmune Rheumatic Diseases Living in Dengue-Endemic Areas

NCT07087912 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.

NCT NCT07087912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07087912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine (Butantan-DV) in Patients With Autoimmune Rheumatic Diseases Living in Dengue-Endemic Areas
Lead sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
March 16, 2026
Completion date
December 30, 2028
Enrollment
477 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome, axial spondyloarthritis, granulomatosis with polyangiitis, idiopathic inflammatory myopathies (iims), juvenile idiopathic arthritis (jia), juvenile systemic lupus erythematosus, microscopic polyangiitis, psoriatic arthritis (psa), rheumatoid arthritis (ra), systemic lupus erythematosus (sle), systemic sclerosis (ssc), takayasu arteritis